← Issue №12/ week of Sep 20, 2026/Endoscopy

EUS-Guided Cyanoacrylate Injection With Balloon-Compression Sclerotherapy Versus Band Ligation for Gastroesophageal Varices: A Randomized Trial.

From GI Signals issue №12: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Endoscopy rct · n=124 · Sep 17, 2026 · J Gastro Hep · IF 3.5

EUS-Guided Cyanoacrylate Injection With Balloon-Compression Sclerotherapy Versus Band Ligation for Gastroesophageal Varices: A Randomized Trial.

New evidencevariceal bleedingendoscopy qualityEUS
Clinical takeawayConsider EUS-guided cyanoacrylate injection combined with balloon-compression sclerotherapy (EUS-CYA + bc-EIS) over EUS-CYA + EVL for cirrhotic patients with gastroesophageal varices, as it improves eradication and reduces treatment sessions, though the rebleeding difference was not statistically significant.
What it foundEUS-CYA + bc-EIS achieved 100% esophageal variceal eradication vs. 82.3% with EUS-CYA + EVL, with fewer sessions (1.4 vs. 2.1) and lower rebleeding (9.7% vs. 21.0%, p=0.081).
ContextRefines current practice: EUS-CYA + bc-EIS outperforms EUS-CYA + EVL in esophageal variceal eradication and session efficiency, with comparable safety, in cirrhotic patients with GOV.
Refinessuggested applicable standard· AASLD, 'Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis', Hepatology 2024 (PMID 37870298), the governing document for acute variceal hemorrhage. Baveno VII (J Hepatol 2022, PMID 35120736) is the consensus it operationalises. The prior citation, ACG 'Disorders of the Hepatic and Mesenteric Circulation' (2020), covers Budd-Chiari, portal vein thrombosis and mesenteric ischemia and does NOT address variceal bleeding, a mis-anchor, not a stale edition.

Decision at stakethe optimal endoscopic approach for concomitant esophageal varices during EUS-guided cyanoacrylate injection for gastric varices

Perform upper endoscopy within 12 hours of presentation once resuscitated, or as soon as safely possible if the patient is unstable, with band ligation for esophageal varices and for GOV1 (which is treated as an esophageal varix); cardiofundal varices (GOV2 and IGV1) are treated with cyanoacrylate injection, with EUS-guided coil placement with or without cyanoacrylate increasingly used as first-line where expertise exists, and TIPS or BRTO as alternatives or salvage.

From our summary of this standard, unedited — the part the paper bears on. marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

For acute variceal hemorrhage in cirrhosis, resuscitate conservatively with a restrictive RBC transfusion strategy targeting hemoglobin 7-8 g/dL, start a vasoactive agent as soon as bleeding is suspected and before endoscopy (terlipressin, somatostatin, or octreotide; octreotide is the agent available for this indication in US practice) and continue it 2-5 days, and give empiric IV ceftriaxone 1 g every 24 hours in patients with advanced cirrhosis. Perform upper endoscopy within 12 hours of presentation once resuscitated, or as soon as safely possible if the patient is unstable, with band ligation for esophageal varices and for GOV1 (which is treated as an esophageal varix); cardiofundal varices (GOV2 and IGV1) are treated with cyanoacrylate injection, with EUS-guided coil placement with or without cyanoacrylate increasingly used as first-line where expertise exists, and TIPS or BRTO as alternatives or salvage. PPIs started empirically should be stopped immediately after endoscopy unless there is a separate strict indication. Evaluate every patient at presentation for pre-emptive (early) TIPS with a PTFE-covered stent, placed within 72 hours and ideally within 24 hours, in high-risk patients defined as Child-Pugh class C with score under 14 (that is, 10-13) or Child-Pugh class B with score above 7 who have active bleeding at initial endoscopy despite vasoactive drugs; the decision is individualized and multidisciplinary, weighing age, frailty, comorbidity, heart failure, HCC, portal vein thrombosis, and transplant candidacy. For uncontrolled bleeding, a self-expanding covered esophageal metal stent is as effective as balloon tamponade and is the safer option; both are a bridge to definitive therapy (PTFE-covered TIPS) and neither is definitive therapy. Balloon tamponade must NOT be left in place for more than 24 hours, 24 hours is the ceiling, not a range: Baveno VI states it "should only be used in refractory oesophageal bleeding, as a temporary bridge (for a maximum of 24 h) with intensive care monitoring and considering intubation, until definitive treatment can be instituted", because severe esophageal injury/necrosis, perforation and aspiration rise sharply beyond that point. The 72-hour figure in this standard belongs to the pre-emptive TIPS window and must not be read as a permissible tamponade duration. Secondary prophylaxis is mandatory in all survivors and is combination therapy: a nonselective beta-blocker, either a traditional NSBB (propranolol or nadolol) or carvedilol, which Baveno VII endorses as an equivalent rather than clearly superior option in this specific indication, plus serial EVL every 2 to 8 weeks until variceal eradication, with surveillance endoscopy thereafter. TIPS is the treatment of choice for patients who rebleed despite NSBB plus EVL.

AASLD, 'Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis', Hepatology 2024 (PMID 37870298), the governing document for acute variceal hemorrhage. Baveno VII (J Hepatol 2022, PMID 35120736) is the consensus it operationalises. The prior citation, ACG 'Disorders of the Hepatic and Mesenteric Circulation' (2020), covers Budd-Chiari, portal vein thrombosis and mesenteric ischemia and does NOT address variceal bleeding, a mis-anchor, not a stale edition. · reviewed 2026-07-31 ↗
Yang X … Kong D · Journal of Gastroenterology and Hepatology · IF 3.5 · PubMed ↗Permalink
← Read the whole of issue №12 Every paper GI Signals surfaces gets a page like this one. All issues